249 related articles for article (PubMed ID: 37509227)
1. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Nardin C; Hennemann A; Diallo K; Funck-Brentano E; Puzenat E; Heidelberger V; Jeudy G; Samimi M; Lesage C; Boussemart L; Peuvrel L; Rouanet J; Brunet-Possenti F; Gerard E; Seris A; Jouary T; Saint-Jean M; Puyraveau M; Saiag P; Aubin F
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509227
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
4. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
Scheiner B; Roessler D; Phen S; Lim M; Pomej K; Pressiani T; Cammarota A; Fründt TW; von Felden J; Schulze K; Himmelsbach V; Finkelmeier F; Deibel A; Siebenhüner AR; Shmanko K; Radu P; Schwacha-Eipper B; Ebert MP; Teufel A; Djanani A; Hucke F; Balcar L; Philipp AB; Hsiehchen D; Venerito M; Sinner F; Trauner M; D'Alessio A; Fulgenzi CAM; Pinato DJ; Peck-Radosavljevic M; Dufour JF; Weinmann A; Kremer AE; Singal AG; De Toni EN; Rimassa L; Pinter M
JHEP Rep; 2023 Jan; 5(1):100620. PubMed ID: 36578451
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
7. REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.
Vauchier C; Auclin E; Barthélémy P; Carril-Ajuria L; Ryckewaert T; Borchiellini D; Castel-Ajgal Z; Bennamoun M; Campedel L; Thiery-Vuillemin A; Coquan E; Crouzet L; Berdah JF; Chevreau C; Ratta R; Fléchon A; Lefort F; Albiges L; Gross-Goupil M; Vano YA; Thibault C; Oudard S
J Oncol; 2022; 2022():3449660. PubMed ID: 35222642
[TBL] [Abstract][Full Text] [Related]
8. Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.
Kim M; Chang CS; Choi MC; Lee JW; Park H; Joo WD
Yonsei Med J; 2023 Oct; 64(10):587-592. PubMed ID: 37727917
[TBL] [Abstract][Full Text] [Related]
9. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.
Shah P; Punekar SR; Pavlick AC
Melanoma Res; 2021 Jun; 31(3):242-248. PubMed ID: 33741813
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
Xu Z; Hao X; Yang K; Wang Q; Wang J; Lin L; Teng F; Li J; Xing P
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3081-3089. PubMed ID: 34982222
[TBL] [Abstract][Full Text] [Related]
11. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
Gupta M; Stukalin I; Meyers D; Goutam S; Heng DYC; Cheng T; Monzon J; Navani V
JAMA Netw Open; 2023 Jun; 6(6):e2319607. PubMed ID: 37351883
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
[TBL] [Abstract][Full Text] [Related]
14. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study.
Lin X; Deng H; Chu T; Chen L; Yang Y; Qiu G; Xie X; Qin Y; Liu M; Xie Z; Ouyang M; Li S; Song Y; Petrella F; Jakopovic M; Tsoukalas N; Solli P; Goto T; Saito Y; Zhou C
Transl Lung Cancer Res; 2022 Nov; 11(11):2289-2305. PubMed ID: 36519018
[TBL] [Abstract][Full Text] [Related]
16. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
Ito S; Asahina H; Honjo O; Tanaka H; Honda R; Oizumi S; Nakamura K; Takamura K; Hommura F; Kawai Y; Ito K; Sukoh N; Yokoo K; Morita R; Harada T; Takashina T; Goda T; Dosaka-Akita H; Isobe H;
Lung Cancer; 2021 Jun; 156():12-19. PubMed ID: 33872943
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
20. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]